Dassault Systèmes to Buy Drug-Safety AI Firm ArisGlobal

Dassault Systèmes has agreed to buy ArisGlobal, a maker of drug-safety and regulatory software for the pharmaceutical industry, for about $1.8 billion in cash plus up to $200 million tied to future AI revenue. The deal hands private-equity owner Nordic Capital a full exit from a company it bought seven years ago and rebuilt into a cloud, AI-native platform.

The French software company said on July 23, 2026 that it signed a definitive agreement to acquire the business, with the purchase unanimously approved by its board and funded entirely from cash on its balance sheet. The transaction is expected to close in the second half of 2026, subject to regulatory approvals.

The structure is worth reading closely. The $1.8 billion is fixed cash at closing; the additional $200 million is contingent, payable only if ArisGlobal hits multi-year targets for AI-related revenue. Dassault is paying the base price for the business as it stands and asking the “AI-native” premium to prove itself in the numbers before the last tranche changes hands.

A clean exit for Nordic Capital

For Nordic Capital, the sale caps a textbook private-equity hold. The Stockholm-based firm first backed ArisGlobal in 2019, bought an additional stake from the founding family in 2021, and spent the years in between moving the company off legacy, on-premise software and onto a subscription model. It also bolted on two smaller companies, regulatory-content specialist Amplexor Life Science and SPORIFY, to widen the platform.

The financial arc is the part that matters to other investors watching healthcare-software valuations. ArisGlobal generated roughly $100 million in revenue when Nordic Capital first invested; Dassault now expects it to bring in about $175 million in 2026. The cash portion alone values the company at roughly ten times that forward revenue. Nordic Capital never disclosed what it paid in 2019, though the purchase was reported at around $700 million, which would imply a return of about two and a half times its money before the earnout.

Underpinning the price is a business that has become deeply embedded in pharma back offices. ArisGlobal’s LifeSphere platform serves more than 200 customers, including half of the world’s 50 largest biopharma companies, and processes over 12 million patient-safety reports a year. Its newer product, NavaX, applies generative AI to safety-case processing and, the company says, delivers more than 30% productivity gains. That AI layer is what turned a steady compliance-software vendor into an asset a strategic buyer would pay a growth multiple for.

Why Dassault is paying up

Dassault Systèmes is best known for the design and simulation software that Airbus, Boeing and carmakers use, but life sciences has become its most active area of dealmaking. ArisGlobal is its second-largest acquisition in the sector after Medidata, the clinical-trial software group it bought in 2019 for about $5.8 billion.

The logic is consolidation of the drug-development software stack. Medidata sits at the center of clinical-trial execution; ArisGlobal runs the regulatory submissions, drug-safety monitoring and post-market surveillance that surround it; and Dassault’s BIOVIA tools handle the science upstream. Stitching them together gives Dassault a claim few rivals can match: a single vendor spanning discovery, trials, manufacturing and regulated operations. The company frames it as a “continuous evidence loop” that pairs real-world patient data with its simulation expertise.

Dassault projects the compliance-software market it is buying into will grow at a double-digit rate to reach $7.5 billion by 2030, with AI capturing a rising share of that spend. It expects the acquisition to add to revenue growth and earnings per share in its first year, and paying entirely in cash leaves its balance sheet intact for further deals. The move mirrors a broader pattern of strategic buyers paying premium prices for AI-native software rather than building it, visible in deals like EXL’s acquisition of data-labeling firm iMerit.

What to watch

The deal still needs regulatory clearance in a market where the same handful of large pharmaceutical companies are the buyers for most of this software, which makes competition reviews worth watching. If it closes as planned, the pressure shifts to vendors that sell only a slice of the clinical or safety stack: once a buyer can get trial design, drug safety and regulatory filing under one contract, switching costs rise and standalone tools get harder to defend. It is also another data point in the wave of capital chasing AI built for scientific and regulated industries, where the winners increasingly get acquired rather than scaled to independence.